Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31636 | 0.78 | GRIK1 (0.48) | GRIK1GRIK2CYP2C19CPA1ABCC4 | |
| SCHEMBL4021287 | 0.78 | CPA1 (0.44) | GRIK1GRIK2CYP2C19CPA1ABCC4 | |
| SCHEMBL9709901 | 0.78 | SLC1A2 (0.38) | GRIK1GRIK2CYP2C19CPA1 | |
| SCHEMBL19899237 | 0.78 | CYP2C19 (0.49) | CYP2C19CPA1 | |
| SCHEMBL19899203 | 0.78 | CYP2C19 (0.49) | CYP2C19CPA1 | |
| SCHEMBL19899202 | 0.78 | CYP2C19 (0.49) | CYP2C19CPA1 | |
| SCHEMBL7600448 | 0.76 | GRIK1 (0.48) | GRIK1GRIK2CYP2C19CPA1ABCC4 | |
| SCHEMBL28385153 | 0.76 | TSHR (0.38) | GRIK1GRIK2MAPT | |
| Potassium SCHEMBL31299609 | 0.76 | GRIK1 (0.46) | GRIK1GRIK2CYP2C19CPA1ABCC4 | |
| SCHEMBL31299617 | 0.76 | GRIK1 (0.46) | GRIK1GRIK2CYP2C19CPA1ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155640-A1 | Surface Functionalised Nanoparticles | NANOCO TECHNOLOGIES LTD. (GB) | 2014-06-05 | — | — | US | disclosed |
| US-8394976-B2 | Surface functionalised nanoparticles | Nanoco Technologies, Ltd. (GB) | 2013-03-12 | — | — | US | disclosed |
| US-8394976-B2 | Surface functionalised nanoparticles | Nanoco Technologies, Ltd. (GB) | 2013-03-12 | — | — | US | disclosed |
| US-20100113813-A1 | SURFACE FUNCTIONALISED NANOPARTICLES | NANOCO TECHNOLOGIES LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
| US-20100113813-A1 | SURFACE FUNCTIONALISED NANOPARTICLES | NANOCO TECHNOLOGIES LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
| US-20100068522-A1 | Surface Functionalised Nanoparticles | NANOCO TECHNOLOGIES LIMITED (GB) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155640-A1 | Surface Functionalised Nanoparticles | EPCAM, L1CAM, CD4 | GRIK1 3904/4885GRIK2 4179/4885CYP2C19 2707/4885 |
| US-20100113813-A1 | SURFACE FUNCTIONALISED NANOPARTICLES | CD47, CD63, EPCAM | GRIK1 4591/4885GRIK2 4513/4885CYP2C19 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.